Showing posts with label steroid treatment. Show all posts
Showing posts with label steroid treatment. Show all posts

Sunday, 16 August 2009

Steroids helpful in minimizing heart damage in children with Kawasaki's disease

Steroids possess a unique ability to significantly minimize heart damage in children with Kawasaki's disease, according to a study published in an issue of Pediatrics.

The new finding of this study addresses a gap in knowledge as the current guidelines from the the American Academy of Pediatrics state that enough evidence for steroid treatment is lacking and recommendations are been made for the standard treatment of Kawasaki's via aspirin and intravenous immunoglobulin (IVIG).

From News-Medical.Net:
"This gap in knowledge led us to examine the benefits of steroids more closely. We looked at research worldwide and were surprised to find eight solid clinical trials showing the value of steroids in significantly reducing heart damage in children with Kawasaki's disease. Steroids, when combined with aspirin and IVGB, reduced the odds of developing inflammation of the heart blood vessels by half," said Stephen Aronoff, MD, lead author of the meta-analysis and Temple University School of Medicine professor and chair of pediatrics.

Aronoff said that a currently underway multi-center study is expected to offer a new paradigm and further evidence in relation with the benefits of steroid treatment for Kawasaki's disease that is believed to be one of the leading causes of acquired heart disease in children inflaming the blood vessels leading to the human heart.

Friday, 31 July 2009

Children taking steroid drugs nephrotic syndrome are protected against bone loss


According to a recently concluded study, children who have been making use of steroid drugs for nephrotic syndrome do not suffer from bone loss, which is a common side-effect of steroid treatments in adults.

Childhood nephrotic syndrome, which is believed to affect 3 out of every 100,000 children, is common chronic kidney ailment in children. It weakens ability of the body to remove water and salt from the blood resulting in swelling in the belly, legs, and around the eyes but does not impair the functions of kidney.

From News-Medical.Net:
"Unlike other childhood diseases treated with steroid drugs, such as inflammatory bowel disease or juvenile rheumatoid arthritis, nephrotic syndrome resolves quickly when treated," said pediatric nephrologist Mary B. Leonard, M.D., of The Children's Hospital of Philadelphia, lead author of the study. "We specifically chose steroid-sensitive nephrotic syndrome because we are able to isolate the drug's effects on bones, without having an underlying systemic disease simultaneously affecting the bones."

The team led by Dr. Leonard compared 60 children and adolescents with steroid-sensitive nephrotic syndrome to 195 healthy children. Specialized X- ray measurements showed no signs of osteoporosis, a loss in bone mass, among the nephrotic syndrome patients. The study appeared in the August 26 New England Journal of Medicine.

The researchers made adjustments for body mass index, an important consideration, since 38 percent of the children in the nephrotic syndrome sample were obese (in contrast, only 16 percent of the control subjects were obese, a proportion consistent with the general pediatric population). The disproportionate obesity among children with nephrotic syndrome disappears after the patients discontinue steroid treatments.
"While steroids tend to make children shorter and heavier than healthy children, increased weight is associated with an increase in bone mass," said co-author Babette Zemel, Ph.D., of the Nutrition Center at Children's Hospital. Specifically, whole-body measurements of bone mineral content were higher in children with nephrotic syndrome than in healthy children.
Dr. Leonard was of the view that this study will help in assuring parents and doctors about steroid treatments for helping children suffering with nephrotic syndrome as steroids do not enhance their risk of osteoporosis.

Thursday, 25 June 2009

Deafness due to Immune System Attack can be treated with Steroids

Patients who are fighting from deafness due to an immune system attack can get benefits from the steroid treatment as per a new study of the University of Michigan's Kresge Hearing Research Institute.

Deafness caused by an immune system attack that is also known as autoimmune sensorineural hearing loss or AISNHL, can be treated effectively by steroid treatment after knowing the causes of mysterious hearing loss and the next course of action for treatment of deafness.

This study strongly pointed out that accurate prediction can be given with respect to who all will be able to regain their hearing capabilities with steroid treatment after a direct test for antibodies has been conducted, as per Thomas Carey, Ph.D., senior author, professor and a distinguished research scientist at the U-M Medical School and department chair in the School of Dentistry.

From News-Medical.Net:
Researchers at U-M have been studying IESCA for several years in animals and have found that it may be a main target of the immune system's deafening attack on the inner ear.

IESCA is found in the supporting cells that help make up the organ of Corti, a tiny but crucial structure inside the cochlea, or inner ear.

It is here, inside the organ of Corti, that the ultra-sensitive hair cells are found.
Their movement in response to vibrations creates the nerve signals that are fed to the brain and interpreted as sounds and speech.

It has been seen that damage to the organ of Corti and hair cells, whether due to immune system attack, loud noise, trauma or medications, can diminish or destroy hearing.

By developing a monoclonal antibody, called KHRI-3, that attaches to IESCA in the inner ear, and can be detected in living animal systems and cell cultures, it has allowed the researchers to study IESCA's role in hearing loss in animal models, and show that damage to the inner ear caused by antibodies to IESCA can destroy hearing.

The KHRI-3 antibody creates a staining pattern that resembles a line of tiny wine glasses when it binds to IESCA in the organs of Corti of guinea pigs.

The U-M has patent applications pending in the U.S. and overseas, but Carey says the development of a clinical test for patient antibody to IESCA will take time.
Carey told that almost all of his patients who were put to trial for this study reported nearly improved hearing senses after being cured with steroid treatment after suffering immediate hearing loss post an attack of immune system.

The study was funded by the Ruth and Lynn Townsend Fund, a gift from the Holden Foundation, the Autoimmune Sensorineural Hearing Loss Research Fund, the National Institutes of Health, and the Deafness Research Foundation.